ASCO GU 2025 Preview

This discussion dives into groundbreaking findings set to be revealed at the ASCO GU conference. Exciting data on prostate cancer from the TALAPRO2 trial promises new treatment insights. The latest in oligometastatic disease and bladder cancer therapies showcases innovative PSMA-based treatments and antibody-drug conjugates. There's a focus on significant biomarkers, like circulating tumor DNA, that could revolutionize clinical decisions. Moreover, advancements in kidney cancer research highlight new therapies and explore critical issues like racial disparities.